4.1 Review

Multiplex assays for biomarker research and clinical application: Translational science coming of age

Journal

PROTEOMICS CLINICAL APPLICATIONS
Volume 4, Issue 3, Pages 271-284

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200900217

Keywords

Biomarker; Immunoassay; Multiple reaction monitoring; Multiplex assay; Quantitation

Funding

  1. National Heart Lung Blood Institute Proteomic Initiative [N01-HV-28, 120]
  2. SCCOR program (Specialized Centers of Clinically Oriented Research) [1 P50 HL 084,946-01]
  3. Clinical Translational Science Award [1U54RR023561-01A1]
  4. Daniel P. Amos Foundation
  5. Novartis Research Foundation
  6. Swiss National Science Foundation [PBSKP3-124604]
  7. Department of Cardiovascular Surgery, University of Berne
  8. Johns Hopkins Clinical Hematology Development Program [5K12HL087169-04]
  9. NHLBI Proteomics and Genomics Hands-on Workshop [5T15HL086386-04]
  10. American Society of Hematology Clinical Research Training Institute
  11. National Institutes of Health [1 RC1 HL100021-01]
  12. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL100021, T15HL086386, P50HL084946, K12HL087169] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Over the last decade, translational science has come into the focus of academic medicine, and significant intellectual and financial efforts have been made to initiate a multitude of bench-to-bedside projects. The quest for suitable biomarkers that will significantly change clinical practice has become one of the biggest challenges in translational medicine. Quantitative measurement of proteins is a critical step in biomarker discovery. Assessing a large number of potential protein biomarkers in a statistically significant number of samples and controls still constitutes a major technical hurdle. Multiplexed analysis offers significant advantages regarding time, reagent cost, sample requirements and the amount of data that can be generated. The two contemporary approaches in multiplexed and quantitative biomarker validation, antibody-based immunoassays and MS-based multiple (or selected) reaction monitoring, are based on different assay principles and instrument requirements. Both approaches have their own advantages and disadvantages and therefore have complementary roles in the multi-staged biomarker verification and validation process. In this review, we discuss quantitative immunoassay and multiple reaction monitoring/selected reaction monitoring assay principles and development. We also discuss choosing an appropriate platform, judging the performance of assays, obtaining reliable, quantitative results for translational research and clinical applications in the biomarker field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available